Alignment in a clinical trial partnership is the shared understanding of priorities, roles, decision rights, and expectations that allows sponsors and their vendor partners to execute as a coherent system. Most sponsors and CROs assume it exists because they communicated at kick-off, because the contract was signed, because no one raised an objection. But communication is not alignment. A contract is not alignment. The absence of objection is not alignment. Alignment is a shared understanding that has been tested, not one that has been assumed from the presence of agreement in the room. The most persistent and costly assumption in clinical development is that alignment is automatic once a program begins. It is not. The starting point for most downstream misalignment, escalation, and relationship failure is not a specific event. It is the moment when alignment was assumed to exist and no one checked whether it did.
What Alignment Actually Means in a Clinical Partnership
Alignment is used frequently as shorthand for a range of things that are not quite the same. It can mean that both parties have communicated their positions. It can mean that a document has been agreed. It can mean that a kick-off meeting occurred without visible disagreement.
None of these is alignment in the sense that matters for execution.
Alignment, in the context of a clinical development partnership, means that the sponsor team and the vendor team have a genuinely shared understanding of: what the most important priorities are, in a specific enough form that either party could describe them consistently without consulting each other; who makes which decisions, and at what level of urgency those decisions need to be made; what success looks like at the next milestone, and what would need to happen for it to be in question; and what the threshold is for raising a concern before it becomes a problem.
When all of those things are shared and tested, a partnership can absorb unexpected events without losing coherence. When they are assumed rather than verified, the first unexpected event reveals how much was never shared in the first place.
How the Alignment Assumption Forms and Persists
The assumption that alignment exists is understandable, and it forms at a moment that is designed to feel like alignment: the kick-off. Both parties are motivated to present positively. Energy is high. The relationship is new and the program has not yet encountered any of the conditions that will test it. In this environment, it is natural to interpret the absence of disagreement as the presence of agreement.
What is actually being created at kick-off, in most cases, is a shared surface rather than a shared foundation. Both parties know what was communicated. They do not yet know whether they understood it the same way, whether their operational assumptions behind the strategic language are consistent, or whether their expectations about how the partnership will function under pressure are compatible.
| Alignment Approach | When It Is Established | When It Typically Fails |
|---|---|---|
| Assumed alignment | Implied at contract signing; treated as stable throughout | First unplanned scenario: a scope change, a resourcing issue, an escalation |
| Declared alignment | Stated at kick-off; not tested across both parties | Months two to three, when priorities diverge and no one surfaces the difference |
| Active alignment | Tested at kick-off and revisited deliberately throughout execution | Rarely fails; when differences emerge, they are surfaced early and addressed before they cascade |
Sabine Hutchison, Co-Founder and Co-CEO at Seuss+, has observed across more than 13 years and over 40 clinical development engagements that when sponsors are asked directly whether alignment was tested before execution began, the most common answer is that kick-off was the last moment it was actively addressed. What follows from that answer is a description of the first scenario in which the assumption failed, and when that happened, and what it cost to address.
The assumption is not a sign of poor planning. It is the consequence of an industry that has normalised treating kick-off as the completion of the alignment process rather than its beginning.
What Misalignment Costs When Discovered Late
The cost of misalignment is not linear. It compounds.
A misalignment discovered in week two of a program, when it is a difference in assumption rather than a difference in execution output, can typically be addressed through a direct conversation and a clarification of expectations. The same misalignment discovered in week eight, after execution has been proceeding against two different sets of priorities, has by that point affected planning, resourcing, delivery timelines, and potentially contractual commitments on multiple sides.
What makes this pattern so consistently expensive is that the misalignment is usually not hidden. It is present in the questions that were not asked at kick-off, in the reporting that was not challenged, in the scope conversations that were had informally rather than through the governance structure, and in the expectations that were held by each party without ever being shared with the other. Each of those moments is a visible signal. They are visible, however, only to someone who is looking for them.
Research from the Tufts Center for the Study of Drug Development has documented that organisational and governance factors, including alignment and relationship failures, account for a significant and disproportionate share of avoidable cost increases across Phase 2 and Phase 3 clinical programs. The specific proportions vary, but the consistent finding is that what goes wrong in clinical development is more often about how the parties work together than about the science, the protocol, or the vendor’s technical capability.
Testing Alignment Before Execution Depends on It
The most valuable alignment activity in a clinical partnership is the one that happens before execution begins, not after it does. This means creating structured opportunities to test whether the alignment that appears to exist in a kick-off presentation actually exists in the operational assumptions of the teams who will execute the program.
Useful alignment testing involves asking both parties to describe the same thing independently and comparing the answers: what are the top three risks to the next milestone, described specifically enough that a third party could assess them? What does the sponsor team believe the CRO’s biggest challenge will be in the first month? What does the CRO team believe the sponsor’s biggest constraint is? What decision would each party make if they needed to act quickly without being able to consult the other?
The Vendor Relationship Maximization Method (VRMM), developed by Seuss+ and applied across clinical development programs, begins its first stage, the Strategic Blueprint, with exactly this kind of pre-execution alignment mapping. The intention is not to create a comprehensive document but to surface the assumptions each party is bringing into the program before those assumptions have had time to create divergent execution patterns. Drawing on Seuss+’s experience across 13 years and more than 40 clinical programs, the observation is consistent: programs that invest in testing alignment before execution begins encounter significantly fewer of the avoidable problems that surface when it is assumed instead.
Building a Practice of Active Alignment Across the Trial Lifecycle
Alignment is not a state that can be established once and maintained passively. Conditions change. People change. Priorities shift. The program encounters situations that the parties at kick-off did not anticipate. Each of these changes creates the potential for new misalignment unless alignment is revisited deliberately.
What active alignment looks like in practice is specific and manageable. It means including a deliberate alignment check at each governance milestone, not as a formal agenda item but as a structured question: given what has changed since we last discussed this, what are we assuming about each other’s priorities that we should verify? It means being willing to surface a divergence in understanding when it is observed rather than waiting until it is visible as a problem. And it means treating alignment maintenance as a shared responsibility rather than as something the sponsor defines and the CRO either meets or does not.
The sponsors who navigate clinical programs most effectively under pressure are not necessarily the ones who build the most comprehensive governance structures. They are the ones who maintain genuine operational awareness of what their vendor partners are working with, what they are concerned about, and where their understanding of the program may have diverged from the sponsor’s. That awareness does not come from governance documents. It comes from the practice of asking and verifying rather than assuming and proceeding.
Key Industry Data
- Tufts CSDD, Sources of Clinical Trial Inefficiency: Tufts Center for the Study of Drug Development research has documented that organisational and partnership factors, including expectation misalignment and governance failures, are among the leading contributors to avoidable costs and timeline extensions in late-phase clinical development, with relationship-driven problems accounting for a disproportionate share of program overruns.
- ICH E6(R2), Kick-Off and Initiation Requirements: ICH E6(R2) guidance on trial initiation reinforces that sponsors are responsible for ensuring that all parties understand their responsibilities and the procedures applicable to the trial before it begins. This is a higher standard than communication of expectations; it requires verification of understanding.
- TransCelerate BioPharma, Sponsor-CRO Relationship Research: TransCelerate’s collaborative research on sponsor-CRO relationship quality has identified misaligned expectations at program initiation as among the most consistently cited root causes in post-trial governance reviews, with the gap between what sponsors communicated and what CROs understood frequently larger than either party had recognised at the time.
- Applied Clinical Trials Industry Surveys: Industry surveys on clinical trial execution challenges have consistently identified sponsor-CRO misalignment as a top-three source of program problems, with respondents noting that the misalignment was often present from the early weeks of execution but not surfaced until it had accumulated into a visible problem.
- FDA Guidance on Sponsor Responsibilities, Investigational New Drug Applications: FDA guidance reinforces that sponsors must ensure all parties involved in a clinical trial are fully informed of and in agreement on their roles and responsibilities before trial initiation, framing alignment as an active obligation rather than a passive outcome of communication.
Questions this perspective tends to raise
What is the difference between assumed alignment and active alignment in a clinical trial?+
Assumed alignment is the belief that sponsors and their vendor partners share a common understanding of priorities, roles, and expectations because those things were communicated at the start of the program. Active alignment is the ongoing practice of testing, verifying, and maintaining that shared understanding throughout the life of the trial. Assumed alignment treats alignment as a state created at kick-off. Active alignment treats it as a practice requiring deliberate effort at each phase of the program.
How do you test whether a sponsor and CRO are truly aligned before execution begins?+
Testing alignment before execution begins involves asking both parties to articulate their understanding of priorities, risks, and success criteria independently, rather than confirming agreement with the sponsor’s stated version. Ask the CRO leadership to describe the sponsor’s top priorities in their own words. Ask both parties to identify the scenarios most likely to create significant program risk and compare the answers. Alignment that exists only at the surface of a kick-off presentation will not hold under pressure.
What are the early signs that alignment is breaking down in a clinical development partnership?+
Early signs include: scope creep that is not being flagged; the CRO and sponsor teams operating on different versions of what the current priority is; governance meetings where both parties seem to agree but decisions do not reflect shared commitment; an increase in informal communications that bypass the governance structure; and a growing gap between what the sponsor believes is happening and what the operational data shows.
How often should alignment be revisited during a clinical trial?+
Alignment should be revisited at defined program milestones, at the point of any significant change in scope, personnel, or priority, and at regular governance checkpoints throughout the trial. The useful working principle is to revisit alignment whenever something in the program has changed enough that the assumptions from the previous alignment conversation may no longer hold.
What does misalignment cost in a Phase 2 or Phase 3 clinical program?+
Misalignment costs compound across multiple dimensions. Direct costs include scope disputes, change order negotiations, and remediation of work completed against misaligned assumptions. Indirect costs include timeline slippage from unresolved escalations, resource duplication, and relationship damage. Research from Tufts CSDD has consistently documented that organisational and governance factors, including alignment failures, account for a significant proportion of avoidable cost increases in late-phase clinical development. —
In context
This argument sits inside an industry where the cost of every clinical program is rising and the margin for recovering from a governance error is narrowing. The two numbers below are the shape of that pressure.
The most expensive assumption in clinical development is that alignment already exists.
